MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases.
Merrimack Pharmaceuticals Inc (previously Atlantic Biopharmaceuticals) is developing MM-093 (formerly ABI-001), an injectable formulation of a recombinant human alpha-fetoprotein, for the potential treatment of myasthenia gravis, multiple sclerosis, rheumatoid arthritis, autoimmune uveitis and psoriasis. MM-093 is currently undergoing phase II clinical trials for rheumatoid arthritis, psoriasis and autoimmune uveitis.
Institute of Engineering Immunology, 142380 Lyubuchany, Moscow Region, Chekchov District, Russia. elena_dudich@mail.ru
Elena
E
Dudich
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*; D000509:alpha-Fetoproteins / Q000627:therapeutic use*
C097353:AFP protein, human; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins